サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1729070

ELAHEREの世界市場：2034年までの市場の機会と戦略

Elahere Global Market Opportunities And Strategies To 2034

出版日
ページ情報
英文 249 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
ELAHEREの世界市場：2034年までの市場の機会と戦略
出版日: 2025年05月20日
発行: The Business Research Company
ページ情報: 英文 249 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ELAHERE（ミルベツキシマブ・ソラブタンシン・ジンクス）は、葉酸受容体α（FRa）陽性の卵巣がん、卵管がん、原発性腹膜がんの成人患者の治療を目的とした処方薬です。プラチナ製剤をベースとした化学療法が奏効しなかった、または奏効しなくなった患者で、過去に1～3種類の化学療法を受けたことがある人に特に適応があります。ELAHEREは、抗体薬物複合体（ADC）として機能し、FRa陽性のがん細胞に直接細胞傷害性薬剤を送達することにより、健常組織へのダメージを最小限に抑えます。

ELAHERE市場は、葉酸受容体α（FRa）を高発現するプラチナ製剤抵抗性の上皮性卵巣がん、卵管がん、原発性腹膜がんを治療するために特別に設計された標的抗体薬物複合体（ADC）であるELAHERE（mirvetuximab soravtansine-gynx）の事業体（組織、個人事業主、パートナーシップ）による販売で構成されます。

世界のELAHEREの市場規模は、2024年には5億256万米ドルに達しました。実績期間の成長は、技術の進歩と個別化医療に対する需要の増加に起因しています。

ヘルスケア支出の増加

ヘルスケア支出の増加は、この実績期間におけるELAHERE市場の拡大を支えました。ヘルスケア支出とは、医療費への支出を指し、特定の医療制度や経済圏内でヘルスケア関連の商品やサービスに費やされる総額のことです。ヘルスケア分野の財源が増加することで、革新的な治療や研究開発への投資が拡大します。この資金は、臨床試験、規制当局の承認、ELAHEREのような最先端治療薬の生産規模拡大に伴う高コストをカバーするのに役立ちます。例えば、米国を拠点とする非営利団体Canadian Institute for Health Informationによると、2023年にはカナダの総医療費は3,440億米ドル（1人当たり8,740ドル）に達すると推定されています。医師支出の伸びは、2023年には6.9％、2022年には9.5％と推定されました。したがって、ヘルスケア支出の増加がエラヘルの市場成長を牽引しました。

Abbvie、プラチナ製剤抵抗性卵巣がんにおけるエラヘアの欧州承認を取得

ELAHERE市場の各社は、プラチナ製剤抵抗性卵巣がん患者に対する治療可能性を拡大するため、規制当局の承認取得に注力しています。この動きは、高度な治療オプションを必要とする特定の患者群に標的治療を提供することで、市場での地位を強化することを目的としています。例えば、米国のバイオテクノロジー企業であるAbbvieは、2024年11月、葉酸受容体α（FRα）陽性のプラチナ製剤抵抗性卵巣がん成人患者に対する治療薬として、欧州委員会からエラヘアの承認を取得しました。今回の承認は、第III相臨床試験であるMIRASOL試験の良好な結果に基づいており、標準的な化学療法と比較して、病勢進行または死亡のリスクが35％減少することが示されました。

世界のELAHERE市場は非常に集中しており、参入企業は1社のみです。2023年には、市場トップの競合企業が市場全体の100.0%を占めています。

The Business Research Companyの『ELAHERE Global Market Opportunities And Strategies To 2034』は、戦略担当者、マーケティング担当者、上級管理職を対象に、COVID-19の閉鎖から立ち上がる世界のELAHERE市場を評価するために必要な重要情報を提供しています。

購入の理由

  • 10地域をカバーするこの市場に関する最も包括的なレポートにより、真に世界な視点を得ることができる
  • 市場がコロナウイルスからどのような影響を受けているのか、また、ウイルスの影響が和らぐにつれて市場がどのように浮上し、成長していくのかを理解する
  • 現地のデータと分析に基づき、地域別・国別戦略を策定
  • 投資の対象となる成長セグメントを特定
  • 予測データと市場を形成する促進要因と動向を活用し、競合他社を凌駕
  • 最新の市場調査結果に基づいて顧客を理解
  • 主要な競合他社とのパフォーマンスの比較
  • 主要データセット間の関係を活用し、優れた戦略を立てる
  • 信頼性の高い高品質なデータと分析により、社内外のプレゼンテーションをサポートするのに適している

ELAHEREの最大市場、急成長市場はどこか？経済全体、人口動態、他の類似市場との関係は？今後の市場を形成する勢力は何か？ビジネスリサーチ社のエラホール市場世界レポートは、これらすべての質問とその他多くの質問に回答します。

当レポートでは、市場の特徴、規模と成長、セグメンテーション、地域別および国別内訳、競合情勢、市場シェア、市場の動向と戦略について解説しています。市場の歴史をたどり、地域別の市場成長を予測しています。また、同市場をELAHERE市場全体の中で位置づけ、他市場との比較も行っています。

当レポートは以下の章をカバーしています。

  • イントロダクションと市場特性-臨床適応症別、流通チャネル別、エンドユーザー別など、市場セグメンテーションを簡単に紹介し、定義や解説を加えています。
  • 世界の主な動向-世界市場を形成する主な動向をハイライト。また、今後の市場開拓についても取り上げます。
  • 成長分析と戦略的分析フレームワークPESTEL、最終用途産業、市場成長率、世界の実績（2019年～2024年）および予測（2024年～2029年、2034年）市場値、歴史的および予測期間における市場の成長を支え、抑制する要因、予測成長貢献者、総アドレス可能市場（TAM）に関する分析。
  • 地域別・国別分析-地域別・国別の過去（2019年～2024年）と予測（2024年～2029年、2034年）の市場価値と成長率、市場シェア比較。
  • 市場セグメンテーション-市場における臨床適応症別、流通チャネル別、エンドユーザー別の市場価値（2019年～2024年）（2024年～2029年、2034年）と各セグメント別の分析を収録。地域市場別の過去（2019年～2024年）、予測（2024年～2029年）、（2029年～2034年）市場価値と成長率、市場シェア比較を掲載。
  • 地域別市場規模と成長率-地域別市場規模（2024年）、地域内各国の過去（2019年～2024年）および予測（2024年～2029年、2034年）市場価値と成長率、市場シェア比較。アジア太平洋、西欧、東欧、北米、南米、中東・アフリカの全地域と各地域内の主要国に関する情報を掲載しています。
  • 競合情勢-市場の競合情勢の詳細、推定市場シェア、主要企業の企業プロファイルを掲載しています。
  • 主要なM&A-市場における最近のM&Aに関する情報を掲載しています。本セクションでは、近年の市場を形成したM&Aに関する主要な財務情報を掲載しています。
  • 市場セグメンテーション-調査結果に基づく市場機会と戦略について、国やセグメントごとの成長機会や、それらの市場で取るべき戦略に関する情報を記載しています。
  • 結論・提言-このセクションでは、製品・サービスの提供地域拡大、マーケティング戦略、ターゲットグループなど、エラウェアプロバイダーへの提言を掲載しています。
  • 付録：当レポートで使用されているNAICSコード、略語、通貨コードの詳細が記載されています。

当レポートは、世界のELAHERE市場について調査し、市場の概要とともに、臨床適応症別、流通チャネル別、エンドユーザー別、地域・国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

  • ELAHERE-市場の魅力とマクロ経済情勢

第2章 目次

第3章 テーブル一覧

第4章 図表一覧

第5章 レポートの構成

第6章 市場の特徴

  • 一般的な市場定義
  • サマリー
  • ELAHERE市場の定義とセグメンテーション
  • 臨床適応症別市場セグメンテーション
    • 卵巣腫瘍
    • 卵管腫瘍
    • 腹膜腫瘍
  • 流通チャネル別市場セグメンテーション
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • エンドユーザー別市場セグメンテーション
    • 病院
    • 専門センター
    • その他

第7章 ELAHERE市場の生物学的医薬品の特徴

  • 分子タイプ
  • 投与経路（ROA）
  • 作用機序（MOA）
  • 安全性と有効性

第8章 主要な市場動向

  • Abbvieがプラチナ製剤耐性卵巣がん治療薬「ELAHERE」の欧州承認を取得
  • 進行卵巣がん治療における戦略的連携目標
  • 先進的な診断ツールが卵巣がん治療の向上を目指す

第9章 世界ELAHERE成長分析と戦略分析フレームワーク

  • 世界ELAHERE PESTEL分析（政治、社会、技術、環境、法的要因）

第10章 B2B市場のエンドユーザーの分析

  • エンドユーザー
  • 世界市場規模と成長
  • 市場規模
  • 市場成長実績、2019年～2024年
  • 市場成長予測、2024年～2029年、2034年
  • 世界のELAHERE総獲得可能市場（TAM）

第11章 世界のELAHEREの価格分析と予測

第12章 世界ELAHERE市場セグメンテーション

  • 世界のELAHERE市場、臨床適応症別
  • 世界のELAHERE市場、流通チャネル別
  • 世界のELAHERE市場、エンドユーザー別

第13章 臨床適応症の世界の疫学

  • 臨床適応症の発生率と有病率

第14章 ELAHERE市場、地域別・国別分析

  • 世界のELAHERE市場、地域別、実績および予測、2019年～2024年、2029年、2034年
  • 世界のELAHERE市場、国別、実績および予測、2019年～2024年、2029年、2034年

第15章 アジア太平洋市場

第16章 西欧市場

第17章 東欧市場

第18章 北米市場

第19章 南米市場

第20章 中東市場

第21章 アフリカ市場

第22章 競合情勢と企業プロファイル

  • 企業プロファイル
  • AbbVie Inc.（ImmunoGen）

第23章 世界ELAHERE市場のパイプライン分析

第24章 主要な合併と買収

  • AbbVieがImmunoGenを買収

第25章 機会と戦略

  • 2029年の世界のELAHERE市場- 最も新しい機会を提供する国
  • 2029年の世界のELAHERE市場- 最も新たな機会を提供するセグメント
  • 2029年の世界のELAHERE市場- 成長戦略

第26章 ELAHERE市場、結論・提言

第27章 付録

目次
Product Code: o&s1535

Elahere (mirvetuximab soravtansine-gynx) is a prescription medication designed for the treatment of adult patients with folate receptor-alpha (FRa) positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is specifically indicated for individuals who have not responded to or are no longer responding to platinum-based chemotherapy and have received one to three prior types of chemotherapy. Elahere functions as an antibody-drug conjugate (ADC), delivering a cytotoxic agent directly to FRa-positive cancer cells, thereby minimizing damage to healthy tissues.

The elahere market consists of sales, by entities (organizations, sole traders or partnerships), of elahere (mirvetuximab soravtansine-gynx), a targeted antibody-drug conjugate (ADC) specifically designed for treating platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers that express high levels of folate receptor-alpha (FRa).

The global elahere market accounted to $502.56 million in 2024. The growth in the historic period can be attributed to technological advancements and increase in demand for personalized medicine.

Rising Healthcare Expenditure

The rising healthcare expenditure supported the expansion of the elahere market during this historic period. Healthcare expenditure refers to spending on healthcare costs and represents the total amount of money spent on healthcare-related goods and services within a given healthcare system or economy. Increased financial resources in the healthcare sector enable greater investment in innovative treatments, research and development. This funding helps cover the high costs associated with clinical trials, regulatory approvals and the scaling of production for cutting-edge therapies like Elahere. For instance, in 2023, according to the Canadian Institute for Health Information, a US-based not-for-profit organization, Canada's total health spending was estimated to reach $344 billion, or $8,740 per person. The growth in physician spending was estimated to be 6.9% in 2023 and 9.5% in 2022. Therefore, rising healthcare expenditure drove the growth of the elahere market.

Abbvie Secures European Approval For Elahere In Platinum-Resistant Ovarian Cancer

Companies in the elahere market are focusing on obtaining regulatory approvals to expand the treatment's availability for patients with platinum-resistant ovarian cancer. This move aims to strengthen its position in the market by offering a targeted therapy for a specific patient group in need of advanced treatment options. For instance, in November 2024, AbbVie, a US-based biotech company received approval from the European Commission for elahere as a treatment for adult patients with folate receptor-alpha (FR alpha) positive, platinum-resistant ovarian cancer. The approval was based on the positive results from the Phase III MIRASOL trial, which demonstrated a 35% reduction in the risk of disease progression or death compared to standard chemotherapy.

The global elahere market is highly concentrated, with only one player in the market. The top competitor in the market made up 100.0% of the total market in 2023.

Elahere Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global elahere market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for elahere? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The elahere market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider elahere market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by clinical indication, by distribution channel and by end-users.
  • Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
  • Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
  • Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by clinical indication, by distribution channel and by end-users in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for elahere providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Clinical Indication: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
  • 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 3) By End-User: Hospitals; Specialty Centers; Other End-Users
  • Companies Mentioned: AbbVie Inc. (ImmunoGen)
  • Countries: China; Australia; India; Japan; South Korea; USA; Canada; France; Germany; UK
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; elahere indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Elahere - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Elahere Market Definition And Segmentations
  • 6.4 Market Segmentation By Clinical Indication
    • 6.4.1 Ovarian Neoplasms
    • 6.4.2 Fallopian Tube Neoplasms
    • 6.4.3 Peritoneal Neoplasms
  • 6.5 Market Segmentation By Distribution Channel
    • 6.5.1 Hospital Pharmacies
    • 6.5.2 Retail Pharmacies
    • 6.5.3 Online Pharmacies
  • 6.6 Market Segmentation By End-Users
    • 6.6.1 Hospitals
    • 6.6.2 Specialty Centers
    • 6.6.3 Other End-Users

7 Elahere Market Biologic Drug Characteristics

  • 7.1 Molecule Type
  • 7.2 Route Of Administration (ROA)
  • 7.3 Mechanism Of Action (MOA)
  • 7.4 Safety And Efficacy

8 Major Market Trends

  • 8.1 Abbvie Secures European Approval For Elahere In Platinum-Resistant Ovarian Cancer
  • 8.2 Strategic Collaboration Targets For Advanced Ovarian Cancer Treatment
  • 8.3 Advanced Diagnostic Tool Aims to Enhance Ovarian Cancer Treatment

9 Global Elahere Growth Analysis And Strategic Analysis Framework

  • 9.1 Global Elahere PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors)
    • 9.1.1 Political
    • 9.1.2 Economic
    • 9.1.3 Social
    • 9.1.4 Technological
    • 9.1.5 Environmental
    • 9.1.6 Legal

10 Analysis Of End Users For B2B Markets

  • 10.1 End Users
    • 10.1.1 Hospitals
    • 10.1.2 Specialty Centers
    • 10.1.3 Other End Users
  • 10.2 Global Market Size and Growth
  • 10.3 Market Size
  • 10.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
    • 10.4.1 Market Drivers 2019 - 2024
    • 10.4.2 Market Restraints 2019 - 2024
  • 10.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
    • 10.5.1 Market Drivers 2024 - 2029
    • 10.5.2 Market Restraints 2024 - 2029
  • 10.6 Global Elahere Total Addressable Market (TAM)

11 Global Elahere Pricing Analysis & Forecasts

12 Global Elahere Market Segmentation

  • 12.1 Global Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.2 Global Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.3 Global Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Global Elahere Epidemiology Of Clinical Indications

  • 13.1 Incidence And Prevalence of Clinical Indications

14 Elahere Market, Regional and Country Analysis

  • 14.1 Global Elahere Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.2 Global Elahere Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 Asia-Pacific Market

  • 15.1 Market Overview
    • 15.1.1 Region Information
    • 15.1.2 Background Information
    • 15.1.3 Government Initiatives
    • 15.1.4 Regulations
    • 15.1.5 Regulatory Bodies
    • 15.1.6 Major Associations
    • 15.1.7 Taxes Levied
    • 15.1.8 Corporate Tax Structure
    • 15.1.9 Investments
  • 15.2 Asia-Pacific Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.3 Asia-Pacific Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.4 Asia-Pacific Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.5 Asia-Pacific Elahere Market: Country Analysis
  • 15.6 China Market
  • 15.7 Market Overview
    • 15.7.1 Country Information
    • 15.7.2 Background Information
    • 15.7.3 Government Initiatives
    • 15.7.4 Regulations
    • 15.7.5 Regulatory Bodies
    • 15.7.6 Major Associations
    • 15.7.7 Taxes Levied
    • 15.7.8 Corporate Tax Structure
    • 15.7.9 Investments
  • 15.8 China Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.9 China Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.10 China Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.11 India Market
  • 15.12 India Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.13 India Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.14 India Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.15 Japan Market
  • 15.16 Market Overview
    • 15.16.1 Country Information
    • 15.16.2 Background Information
    • 15.16.3 Regulations
    • 15.16.4 Regulatory Bodies
    • 15.16.5 Major Associations
    • 15.16.6 Taxes Levied
    • 15.16.7 Corporate Tax Structure
    • 15.16.8 Investments
  • 15.17 Japan Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.18 Japan Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.19 Japan Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.20 Australia Market
  • 15.21 Australia Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.22 Australia Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.23 Australia Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.24 South Korea Market
  • 15.25 Market Overview
    • 15.25.1 Country Information
    • 15.25.2 Background Information
    • 15.25.3 Government Initiatives
    • 15.25.4 Regulations
    • 15.25.5 Regulatory Bodies
    • 15.25.6 Major Associations
    • 15.25.7 Taxes Levied
    • 15.25.8 Corporate Tax Structure
  • 15.26 South Korea Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.27 South Korea Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.28 South Korea Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Western Europe Market

  • 16.1 Summary
  • 16.2 Market Overview
    • 16.2.1 Region Information
    • 16.2.2 Market Information
    • 16.2.3 Background Information
    • 16.2.4 Government Initiatives
    • 16.2.5 Regulations
    • 16.2.6 Regulatory Bodies
    • 16.2.7 Major Associations
    • 16.2.8 Taxes Levied
    • 16.2.9 Corporate tax structure
    • 16.2.10 Investments
  • 16.3 Western Europe Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.4 Western Europe Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.5 Western Europe Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.6 Western Europe Elahere Market: Country Analysis
  • 16.7 UK Market
  • 16.8 UK Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.9 UK Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.10 UK Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.11 Germany Market
  • 16.12 Germany Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.13 Germany Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.14 Germany Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.15 France Market
  • 16.16 France Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.17 France Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.18 France Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Eastern Europe Market

  • 17.1 Summary
  • 17.2 Market Overview
    • 17.2.1 Region Information
    • 17.2.2 Market Information
    • 17.2.3 Background Information
    • 17.2.4 Government Initiatives
    • 17.2.5 Regulations
    • 17.2.6 Regulatory Bodies
    • 17.2.7 Major Association
    • 17.2.8 Taxes Levied
    • 17.2.9 Corporate Tax Structure
  • 17.3 Eastern Europe Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.4 Eastern Europe Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.5 Eastern Europe Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 North America Market

  • 18.1 Summary
  • 18.2 Market Overview
    • 18.2.1 Region Information
    • 18.2.2 Market Information
    • 18.2.3 Background Information
    • 18.2.4 Government Initiatives
    • 18.2.5 Regulations
    • 18.2.6 Regulatory Bodies
    • 18.2.7 Major Associations
    • 18.2.8 Taxes Levied
    • 18.2.9 Corporate Tax Structure
    • 18.2.10 Investments
  • 18.3 North America Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.4 North America Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.5 North America Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.6 North America Elahere Market: Country Analysis
  • 18.7 USA Market
  • 18.8 Summary
  • 18.9 Market Overview
    • 18.9.1 Country Information
    • 18.9.2 Market Information
    • 18.9.3 Background Information
    • 18.9.4 Government Initiatives
    • 18.9.5 Regulations
    • 18.9.6 Regulatory Bodies
    • 18.9.7 Major Associations
    • 18.9.8 Taxes Levied
    • 18.9.9 Corporate Tax Structure
    • 18.9.10 Investments
  • 18.1 USA Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.11 USA Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.12 USA Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.13 Canada Market
  • 18.14 Market Overview
    • 18.14.1 Country Information
    • 18.14.2 Background Information
    • 18.14.3 Government Initiatives
    • 18.14.4 Regulations
    • 18.14.5 Regulatory Bodies
    • 18.14.6 Major Associations
    • 18.14.7 Taxes Levied
    • 18.14.8 Corporate Tax Structure
  • 18.15 Canada Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.16 Canada Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.17 Canada Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

19 South America Market

  • 19.1 Market Overview
    • 19.1.1 Region Information
    • 19.1.2 Background Information
    • 19.1.3 Government Initiatives
    • 19.1.4 Regulations
    • 19.1.5 Regulatory Bodies
    • 19.1.6 Major Associations
    • 19.1.7 Taxes Levied
    • 19.1.8 Corporate Tax Structure
  • 19.2 South America Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 19.3 South America Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 19.4 South America Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

20 Middle East Market

  • 20.1 Market Overview
    • 20.1.1 Region Information
    • 20.1.2 Market Information
    • 20.1.3 Background Information
    • 20.1.4 Government Initiatives
    • 20.1.5 Regulations
    • 20.1.6 Regulatory Bodies
    • 20.1.7 Major Associations
    • 20.1.8 Taxes Levied
    • 20.1.9 Corporate Tax Structure
  • 20.2 Middle East Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 20.3 Middle East Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 20.4 Middle East Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

21 Africa Market

  • 21.1 Market Overview
    • 21.1.1 Region Information
    • 21.1.2 Background Information
    • 21.1.3 Government Initiatives
    • 21.1.4 Regulations
    • 21.1.5 Regulatory Bodies
    • 21.1.6 Major Associations
    • 21.1.7 Taxes Levied
    • 21.1.8 Corporate Tax Structure
  • 21.2 Africa Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 21.3 Africa Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 21.4 Africa Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

22 Competitive Landscape And Company Profiles

  • 22.1 Company Profiles
  • 22.2 AbbVie Inc. (ImmunoGen)
    • 22.2.1 Company Overview
    • 22.2.2 Products And Services
    • 22.2.3 Business Strategy
    • 22.2.4 Financial Overview

23 Global Elahere Market Pipeline Analysis

24 Key Mergers And Acquisitions

  • 24.1 AbbVie Acquired ImmunoGen

25 Opportunities And Strategies

  • 25.1 Global Elahere Market In 2029 - Countries Offering Most New Opportunities
  • 25.2 Global Elahere Market In 2029 - Segments Offering Most New Opportunities
  • 25.3 Global Elahere Market In 2029 - Growth Strategies
    • 25.3.1 Market Trend Based Strategies
    • 25.3.2 Competitor Strategies

26 Elahere Market, Conclusions And Recommendations

  • 26.1 Conclusions
  • 26.2 Recommendations
    • 26.2.1 Product
    • 26.2.2 Place
    • 26.2.3 Price
    • 26.2.4 Promotion
    • 26.2.5 People

27 Appendix

  • 27.1 Geographies Covered
  • 27.2 Market Data Sources
  • 27.3 Research Methodology
  • 27.4 Currencies
  • 27.5 The Business Research Company
  • 27.6 Copyright and Disclaimer